Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry

被引:23
作者
Egeberg, A. [1 ]
Iversen, L. [2 ]
Gniadecki, R. [3 ]
Hvid, L. [4 ,5 ]
Dam, T. N. [6 ]
Bryld, L. E. [7 ]
Skov, L. [1 ]
机构
[1] Univ Copenhagen, Dept Dermatol & Allergy, Herlev & Gentofte Hosp, Hellerup, Denmark
[2] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark
[3] Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark
[4] Odense Univ Hosp, Dept Dermatol, Odense, Denmark
[5] Odense Univ Hosp, Allergy Ctr, Odense, Denmark
[6] Skin Clin, Nykobing, Denmark
[7] Roskilde Hosp, Dept Dermatol, Roskilde, Denmark
关键词
DRUG SURVIVAL; ETANERCEPT; ARTHRITIS; SAFETY;
D O I
10.1111/jdv.14200
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background While safety and efficacy of ustekinumab and secukinumab, monoclonal antibodies approved for psoriasis, are described in clinical trials, data on their real-life application are lacking. Objective We compared the characteristics of patients initiating first-time treatment with secukinumab or ustekinumab. Methods All Danish patients with moderate-to-severe plaque psoriasis treated with biologics are recorded in the nationwide DERMBIO registry. We compared characteristics of patients starting first-time therapy with ustekinumab and secukinumab, respectively. Results We identified a total of 1037 and 142 first-time treatment series with ustekinumab and secukinumab. There was a male predominance in both groups, but patients initiating secukinumab were slightly older and with longer disease duration; in agreement with guidelines for biologic treatment in Denmark where ustekinumab has been first line for all with psoriasis without joint problems since 2012, and secukinumab first line for psoriasis with joint problems since July 2016. A total of (52.9% and 14.5%) patients receiving ustekinumab and secukinumab, respectively, were bio-naive. The mean dermatology life quality index score was slightly higher for ustekinumab than secukinumab (11.6 vs. 10.0; P = 0.0769); the mean Psoriasis Area and Severity Index score were significantly higher (10.4 vs. 7.3; P < 0.0001) for ustekinumab. Prevalence of joint disease was markedly lover (22.7% vs. 44.4%) among patients receiving ustekinumab. Conclusions We found significant differences in characteristics of patients starting therapy with ustekinumab and secukinumab in a real-life clinical setting. These findings may aid clinicians and researchers when interpreting efficacy data derived from clinical trials and biologic registries of patients with psoriasis.
引用
收藏
页码:1183 / 1187
页数:5
相关论文
共 15 条
[1]   Psoriasis [J].
Boehncke, Wolf-Henning ;
Schoen, Michael P. .
LANCET, 2015, 386 (9997) :983-994
[2]   Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris [J].
Gniadecki, R. ;
Bang, B. ;
Bryld, L. E. ;
Iversen, L. ;
Lasthein, S. ;
Skov, L. .
BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (01) :244-252
[3]   Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris [J].
Gniadecki, R. ;
Kragballe, K. ;
Dam, T. N. ;
Skov, L. .
BRITISH JOURNAL OF DERMATOLOGY, 2011, 164 (05) :1091-1096
[4]   The Higher Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men [J].
Hagg, David ;
Eriksson, Marie ;
Sundstrom, Anders ;
Schmitt-Egenolf, Marcus .
PLOS ONE, 2013, 8 (05)
[5]   The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries [J].
Hojgaard, Pil ;
Glintborg, Bente ;
Kristensen, Lars Erik ;
Gudbjornsson, Bjorn ;
Love, Thorvardur Jon ;
Dreyer, Lene .
RHEUMATOLOGY, 2016, 55 (12) :2191-2199
[6]   Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials [J].
Langley, Richard G. ;
Elewski, Boni E. ;
Lebwohl, Mark ;
Reich, Kristian ;
Griffiths, Christopher E. M. ;
Papp, Kim ;
Puig, Lluis ;
Nakagawa, Hidemi ;
Spelman, Lynda ;
Sigurgeirsson, Bardur ;
Rivas, Enrique ;
Tsai, Tsen-Fang ;
Wasel, Norman ;
Tyring, Stephen ;
Salko, Thomas ;
Hampele, Isabelle ;
Notter, Marianne ;
Karpov, Alexander ;
Helou, Silvia ;
Papavassilis, Charis .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (04) :326-338
[7]   Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics [J].
Mease, Philip J. ;
Gladman, Dafna D. ;
Papp, Kim A. ;
Khraishi, Majed M. ;
Thaci, Diamant ;
Behrens, Frank ;
Northington, Robert ;
Fuiman, Joanne ;
Bananis, Eustratios ;
Boggs, Robert ;
Alvarez, Daniel .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (05) :729-735
[8]   Psoriasis 2 - Current and future management of psoriasis [J].
Menter, Alan ;
Griffiths, Christopher E. M. .
LANCET, 2007, 370 (9583) :272-284
[9]   European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015-Short version - EDF in cooperation with EADV and IPC [J].
Nast, A. ;
Gisondi, P. ;
Ormerod, A. D. ;
Saiag, P. ;
Smith, C. ;
Spuls, P. I. ;
Arenberger, P. ;
Bachelez, H. ;
Barker, J. ;
Dauden, E. ;
de Jong, E. M. ;
Feist, E. ;
Jacobs, A. ;
Jobling, R. ;
Kemeny, L. ;
Maccarone, M. ;
Mrowietz, U. ;
Papp, K. A. ;
Paul, C. ;
Reich, K. ;
Rosumeck, S. ;
Talme, T. ;
Thio, H. B. ;
de Kerkhof, P. van ;
Werner, R. N. ;
Yawalkar, N. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (12) :2277-2294
[10]   Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence [J].
Parisi, Rosa ;
Symmons, Deborah P. M. ;
Griffiths, Christopher E. M. ;
Ashcroft, Darren M. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 (02) :377-385